Taysha Gene Therapies (TSHA) to Release Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) is expected to post its quarterly earnings results before the market opens on Wednesday, February 26th. Analysts expect Taysha Gene Therapies to post earnings of ($0.08) per share and revenue of $2.05 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $1.61 on Monday. The firm has a market capitalization of $329.95 million, a price-to-earnings ratio of 2.56 and a beta of 0.92. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The firm has a 50 day moving average of $1.70 and a 200 day moving average of $1.99. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group upped their price target on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research report on Monday, January 6th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $6.63.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.